These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15614340)

  • 1. Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes.
    Hubacek J; Verma S; Shewchuk L; Ross SJ; Edwards A; Anderson TJ
    Can J Cardiol; 2004 Dec; 20(14):1449-53. PubMed ID: 15614340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
    Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone reduces urinary albumin excretion in type II diabetes.
    Bakris G; Viberti G; Weston WM; Heise M; Porter LE; Freed MI
    J Hum Hypertens; 2003 Jan; 17(1):7-12. PubMed ID: 12571611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
    Hetzel J; Balletshofer B; Rittig K; Walcher D; Kratzer W; Hombach V; Häring HU; Koenig W; Marx N
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1804-9. PubMed ID: 16002742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
    Campia U; Matuskey LA; Panza JA
    Circulation; 2006 Feb; 113(6):867-75. PubMed ID: 16461819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents: 2004.
    Lebovitz HE
    Med Clin North Am; 2004 Jul; 88(4):847-63, ix-x. PubMed ID: 15308382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
    Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass.
    Lucotti P; Monti L; Setola E; La Canna G; Castiglioni A; Rossodivita A; Pala MG; Formica F; Paolini G; Catapano AL; Bosi E; Alfieri O; Piatti P
    Metabolism; 2009 Sep; 58(9):1270-6. PubMed ID: 19592054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    McGill JB
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.
    Raji A; Gerhard-Herman MD; Williams JS; O'connor ME; Simonson DC
    Diabet Med; 2006 May; 23(5):537-43. PubMed ID: 16681563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
    Shargorodsky M; Michaelova K; Boaz M; Gavish D; Zimlichman R
    Diabet Med; 2007 Nov; 24(11):1254-60. PubMed ID: 17725634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
    de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
    Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.